Skip to main content
. 2020 Dec 15;17(4):1002–1013. doi: 10.20892/j.issn.2095-3941.2020.0089

Figure 4.

Figure 4

HR-mut status is associated with elevated immune activity and a favorable ICI therapeutic response. (A) The fraction of CD8-positive T cells, as inferred with CIBERSORT, is higher in HR-mut GC than in HR-wt GC. (B) The fraction of CD8-positive T cells shows no significant difference in BRCA1/2-mut GC compared with BRCA1/2-wt GC. (C, D) Cytolytic activity is significantly higher in HR-mut GC (C) and BRCA1/2-mut GC (D) than in the corresponding wt groups. (E, F) The IFN-γ signature is significantly higher in HR-mut GC (E) and BRCA1/2-mut GC (F) than in the corresponding wt groups. P-values were calculated with the Wilcoxon test; the box shows the upper and lower quartiles. (G, H) Kaplan–Meier survival curves show the overall survival (OS) stratified by HR-mut/wt (G) and BRCA1/2-mut/wt (H) in the MSK-IMPACT GC cohort. P-values were obtained with the log-rank test (*P < 0.05; **P < 0.01; ns, P > 0.05).